NEIL2 and non-small cell lung carcinoma: After cisplatin-based chemotherapy, the median progression-free survival (mPFS) time of NSCLC patients bearing “T/T” homozygote in NEIL2 gene rs8191670 locus was 6.1 months (95% CI: 5.0 months - 7.2 months), which was significantly longer than that of the “C/C” homozygote patients (4.5 months, 95% CI: 3.8 months - 5.2 months, P = 0.01).